Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)

References

• International diabetes federation IDF Diabetes Atlas 7th edn Brussels, Belgium International Diabetes Federation 2015 Available from: http://www.diabetesatlas.org Accessed July 27, 2016
   Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2016 Diabetes Care 2016 39 Suppl 1 S1 S106 26696671
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI Consensus statement by the American Association of Clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary Endocr Pract 2016 22 1 84 113 26731084
   PubMed Web of Science ®Google Scholar
• Eto T Inoue S Kadowaki T Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2012 14 11 1040 1046 22776014
   PubMed Web of Science ®Google Scholar
• Scott LJ Teneligliptin: a review in type 2 diabetes Clin Drug Investig 2015 35 11 765 772
   PubMed Web of Science ®Google Scholar
• Kutoh E Hirate M Ikeno Y Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes J Clin Med Res 2014 6 4 287 294 24883155
   PubMedGoogle Scholar
• ORG-IMS June’2016 Available from: https://www.imshealth.com/en/about-us/news/top-line-market-data Accessed July 27,2016
   Google Scholar
• CTRI/2014/01/004315. Available from: http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=8318&EncHid=&userName=teneligliptin. Accessed August 24, 2016.
   Google Scholar
• Silverman SL From randomized controlled trials to observational studies Am J Med 2009 122 2 114 120 19185083
   PubMed Web of Science ®Google Scholar
• Sahay BK Seshiah V Importance of observational studies in understanding regional clinical practice: rationale and design of the A1chieve study J Assoc Physicians India 2013 61 1 Suppl 6 8
   Google Scholar
• Mathieu C Barnett AH Brath H Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE) Int J Clin Pract 2013 67 10 947 956 23961850
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Saglietti G Placentino G Schellino A Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy Clin Drug Investig 2014 34 7 513 519
   Web of Science ®Google Scholar
• Kubota A Maeda H Kanamori A Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients J Diabetes Investig 2012 3 6 503 509
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo K Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Diabetes Obes Metab 2013 15 9 810 818 23464664
   PubMed Web of Science ®Google Scholar
• Hong S Park CY Han KA Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial Diabetes Obes Metab 2016 18 5 528 532 26749529
   PubMed Web of Science ®Google Scholar
• Kim MK Rhee EJ Han KA Efficacy and safety of teneligliptin: a dipeptidyl peptidase 4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial Diabetes Obes Metab 2015 17 3 309 312 25475929
   PubMed Web of Science ®Google Scholar
• Stein SA Lamos EM Davis SN A review of the efficacy and safety of oral antidiabetic drugs Expert Opin Drug Saf 2013 12 2 153 175 23241069
   PubMed Web of Science ®Google Scholar
• Bosetti C Rosato V Buniato D Zambon A La Vecchia C Corrao G Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis Oncologist 2013 18 2 148 156 23345544
   PubMed Web of Science ®Google Scholar
• Abe M Okada K DPP-4 inhibitors in diabetic patients with chronic kidney disease and end-stage kidney disease on dialysis in clinical practice Contrib Nephrol 2015 185 98 115 26023019
   PubMed Web of Science ®Google Scholar
• Nakamura Y Hasegawa H Tsuji M Diabetes therapies in hemodialysis patients: dipeptidase-4 inhibitors World J Diabetes 2015 6 6 840 849 26131325
   PubMedGoogle Scholar
• Halabi A Maatouk H Siegler KE Faisst N Lufft V Klause N Pharmacokinetics of teneligliptin in subjects with renal impairment Clin Pharmacol Drug Dev 2013 2 3 246 254 27121786
   PubMed Web of Science ®Google Scholar
• Halabi A Maatouk H Siegler KE Faisst N Hinrichsen H Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment Clin Pharmacol Drug Dev 2013 3 4 290 296
   Web of Science ®Google Scholar
• Otsuki H Kosaka T Nakamura K Shimomura F Kuwahara Y Tsukamoto T Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes Int Urol Nephrol 2014 46 2 427 432 24014134
   PubMed Web of Science ®Google Scholar
• Wada N Mori K Nakagawa C Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: evaluation by continuous glucose monitoring J Diabetes Complications 2015 29 8 1310 1313 26298521
   PubMed Web of Science ®Google Scholar
• Deacon CF Lebovitz HE Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas Diabetes Obes Metab 2016 18 4 333 347 26597596
   PubMed Web of Science ®Google Scholar
• Foroutan N Muratov S Levine M Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis Clin Invest Med 2016 39 2 E48 E62 27040861
   PubMed Web of Science ®Google Scholar
• Karagiannis T Paschos P Paletas K Matthews DR Tsapas A Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012 344 e1369 22411919
   PubMed Web of Science ®Google Scholar
• Ou SM Shih CJ Chao PW Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus Ann Intern Med 2015 163 9 663 672 26457538
   PubMed Web of Science ®Google Scholar
• Turner RC Cull CA Frighi V Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 2000 281 21 2005 2012
   Web of Science ®Google Scholar
• Yadav D Mishra M Tiwari A Bisen PS Goswamy HM Prasad GB Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance Osong Public Health Res Perspect 2014 5 3 169 175 25180150
   PubMedGoogle Scholar
• Stone NJ Robinson JG Lichtenstein AH 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014 129 25 Suppl 2 S1 S45 24222016
   PubMed Web of Science ®Google Scholar